|
MIXED LINEAGE LEUKEMIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
YEATS mutations induced a gain of function, transforming primary hematopoietic cells in vitro and in transplantation assays through aberrant transcription and H2B ubiquitination of <i>Hoxa9</i> and <i>Meis1</i> Mechanistically, H3 and PAF1 competed for ENL interaction, with activating mutations favoring PAF1 binding, whereas the MLL moiety provided a constitutive PAF1 tether allowing MLL fusions to circumvent H3 competition.
|
29217648 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We find that Paf1 undergoes ubiquitylation and is degraded by the 26S proteasome in yeast, thus deciphering UPS regulation of an evolutionarily conserved factor, Paf1, involved in various cellular processes at the crossroads of the cancer networks.
|
29023102 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
We find that Paf1 undergoes ubiquitylation and is degraded by the 26S proteasome in yeast, thus deciphering UPS regulation of an evolutionarily conserved factor, Paf1, involved in various cellular processes at the crossroads of the cancer networks.
|
29023102 |
2017 |
|
Zellweger Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
This gene encodes a protein that shows similarity to the mammalian PAF1 protein (Zellweger syndrome).
|
7600573 |
1995 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Therefore, the results suggest that the new designed Pt(II) and Pd(II) complexes are well promising candidates for use in cancer treatment, particularly for human colorectal cancer.Communicated by Ramaswamy H. Sarma.
|
30146941 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, the results suggest that the new designed Pt(II) and Pd(II) complexes are well promising candidates for use in cancer treatment, particularly for human colorectal cancer.Communicated by Ramaswamy H. Sarma.
|
30146941 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The treatment of the Pd(II) complex in tumor-bearing mice effectively reduced the tumor size at half the dose used for cisplatin.
|
28657910 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The new synthesized Pd(II) complexes <b>1</b> and <b>2</b> exhibit an important potential through their selective cytotoxic activity and by targeting the stem-like tumor cell populations, which leads to the tumor growth arrest and prevention of metastasis.
|
28358339 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The new synthesized Pd(II) complexes <b>1</b> and <b>2</b> exhibit an important potential through their selective cytotoxic activity and by targeting the stem-like tumor cell populations, which leads to the tumor growth arrest and prevention of metastasis.
|
28358339 |
2017 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.
|
29217648 |
2018 |
|
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis.
|
16491129 |
2006 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The human PAF1 complex is linked to cancer, and in yeast, it has been reported to play a role in telomere biology.
|
29564528 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The human PAF1 complex is linked to cancer, and in yeast, it has been reported to play a role in telomere biology.
|
29564528 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
|
Peroxisome biogenesis disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The first, functional complementation, was established as a viable approach by Fujiki and colleagues, who identified PAF-1, the first known peroxisome biogenesis disorder gene.
|
8993569 |
1996 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity results showed that, the Pd(II) complex of L has higher anti-tumor effect than L and its Pt(II) complex against the tested human breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (LNCAP), and human colon carcinoma (LS174T) cell lines.
|
29216566 |
2018 |
|
Adenocarcinoma of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity results showed that, the Pd(II) complex of L has higher anti-tumor effect than L and its Pt(II) complex against the tested human breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (LNCAP), and human colon carcinoma (LS174T) cell lines.
|
29216566 |
2018 |
|
Breast adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity results showed that, the Pd(II) complex of L has higher anti-tumor effect than L and its Pt(II) complex against the tested human breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (LNCAP), and human colon carcinoma (LS174T) cell lines.
|
29216566 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The Pd(II) complexes have been tested for in vitro cytotoxicity activities against cancer cell line of K<sub>562</sub>.
|
28849726 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The Pd(II) complexes have been tested for in vitro cytotoxicity activities against cancer cell line of K<sub>562</sub>.
|
28849726 |
2018 |
|
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a familial cancer syndrome that can result from germline inactivation of HRPT2/CDC73, a putative tumor suppressor gene that encodes parafibromin, a component of the transcriptional regulatory PAF1 complex with homology to the yeast protein Cdc73p.
|
20304979 |
2010 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The 19q13 amplicon in pancreatic cancer cells contains a novel pancreatic differentiation 2 (PD2) gene (accession number AJ401156), which was identified by differential screening analysis.
|
16491129 |
2006 |